Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.81 +1.51 (+7.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,850,509
Open 20.43
Bid (Size) 21.79 (2)
Ask (Size) 21.83 (10)
Prev. Close 20.30
Today's Range 19.89 - 22.09
52wk Range 10.41 - 144.22
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit

Performance

YTD
-82.4%
-82.4%
1 Month
+19.8%
+19.8%
3 Month
-38.2%
-38.2%
6 Month
-80.1%
-80.1%
1 Year
-83.6%
-83.6%

More News

Read More
SRPT Deadline: Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
Via Stocktwits
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives
Via Investor's Business Daily
Topics Death
August 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
August 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SRPT
Via NewMediaWire
Topics Fraud Lawsuit
Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial
Via Stocktwits
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
From Sarepta Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via NewMediaWire
Topics Fraud Lawsuit
Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
How Do Investors Really Feel About Sarepta Therapeutics?
Via Benzinga
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Via NewMediaWire
Topics Fraud Lawsuit
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
Via MarketBeat
Topics Death
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
SAREPTA (SRPT) LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Shareholders That Lost Money on Sarepta Therapeutics, Inc. (SRPT) Should Contact Levi & Korsinsky About Pending Class Action - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
Shareholders That Lost Money on Sarepta Therapeutics, Inc. (SRPT) Should Contact Levi & Korsinsky About Pending Class Action - SRPT
Via NewMediaWire
Topics Fraud Lawsuit
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Via Benzinga
C3.ai, Destiny Tech100 And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
From Bernstein Liebhard LLP
Via GlobeNewswire
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Trump Ally Laura Loomer Calls Vinay Prasad A ‘Marxist Trojan Horse’ After FDA Rehiring, Slams NASA For Dropping Isaacman
Via Stocktwits
Topics Death Government

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
The current price of Sarepta Therapeutics, Inc. - Common Stock is 21.81
When was Sarepta Therapeutics, Inc. - Common Stock last traded?
The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 08/15/25 04:00 PM ET
What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 2.03B
How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.